Most solid and hematologic malignancies have a prognostication system that helps guide clinical care and patient counseling. For example, TNM staging, consisting of primary tumor characteristics (T), locoregional spread to lymph nodes (N), and distant metastases (M), is commonly used in solid cancers. Similarly, cytogenetic risk, which characterizes the chromosomal abnormalities in the malignant clone, has become standard-of-care for predicting outcome and making therapeutic decisions in many hematologic malignancies. As new genomic marker panels are developed, it is of clinical interest to determine how these markers can help refine and improve the predictive accuracy of an existing classification system. In this talk, we outline a new algorithm for incorporating genomic markers into a classification system and review some initial results. This is joint work with Irina Ostrovnaya and Mithat Gönen.